This study was designed to elucidate how central and peripheral arginine vasopressin (AVP) interacts with the sympathetic nervous system and the renin-angiotensin system to maintain blood pressure in two-kidney, one-clip hypertensive rabbits. We recorded renal sympathetic nerve activity (RSNA) in the conscious state as an index of sympathetic nervous system function. The changes in mean arterial pressure, heart rate, and RSNA were recorded continuously for 60 minutes after intravenous administrations of captopril (2.5 mg/kg) and nicardipine (3.2 ,g * kg-min') in eight identical rabbits. Despite equivalent reductions in mean arterial pressure (10± 1 mm Hg), the increase in RSNA was significantly larger with captopril than that with nicardipine, and the plasma concentration of AVP was elevated (from 100% to 255±24%) with captopril. Mean arterial pressure was reduced, and RSNA was increased by intravenous infusion of AVP antagonist d(CH2)5Tyr(Me)AVP (n=8), whereas vertebral artery infusion of the antagonist (n=6) did not change RSNA. During central and peripheral infusions of AVP antagonist, RSNA was exaggerated by blood pressure reduction with nicardipine as well as with captopril. Increases in RSNA induced by captopril and nicardipine were larger by central infusion of AVP antagonist than by intravenous infusion. The decrease in mean arterial pressure by captopril (30±4 mm Hg) in eight sinoaortic-denervated hypertensive rabbits was larger than that in hypertensive rabbits with intact baroreflex. These data suggest that compensatory activation of RSNA was revealed by central and peripheral attenuation of AVP and that the sympathetic nervous system became the most important mechanism for blood pressure maintenance in the absence of AVP. The interaction of AVP with the sympathetic nervous system may be independent of the state of the renin-angiotensin system, since the exaggeration of RSNA by AVP antagonist was qualitatively the same with nicardipine as with captopril. In conscious renal-hypertensive rabbits, AVP in the central nervous system played a substantial role when blood pressure was reduced, although it did not contribute to blood pressure maintenance in the basal condition. (Circulation Research 1993;72:1255-1265 SNS, and the RAS in renal hypertension, although a redundant interaction between the RAS and SNS has been shown.7 Earlier studies used changes in mean arterial pressure (MAP) and heart rate (HR) in response to ganglionic blockade or 6-hydroxydopamine as indicators of SNS function when examining the interaction of the pressor systems.1-4,8-10 Plasma concentration of norepinephrine has also been used as an index of SNS; however, it does not always reflect the actual state of the SNS, as Folkow et al"l have cautioned.
T he interaction of arginine vasopressin (AVP) with the sympathetic nervous system (SNS) and with the renin-angiotensin system (RAS) in maintaining blood pressure (BP) of normotensive animals is well known.1-3 Hasser et a14 found a close relation between AVP and the SNS in normotensive dogs. Exogenous AVP administered in the cerebroventricle stimulates the SNS,5 and AVP increases the SNS activity in salt-induced hypertensive models.6 In contrast, few studies have examined the role of endogenous AVP in regulating BP and the relation among AVP, the SNS, and the RAS in renal hypertension, although a redundant interaction between the RAS and SNS has been shown. 7 Earlier studies used changes in mean arterial pressure (MAP) and heart rate (HR) in response to ganglionic blockade or 6-hydroxydopamine as indicators of SNS function when examining the interaction of the pressor systems.1-4,8-10 Plasma concentration of norepinephrine has also been used as an index of SNS; however, it does not always reflect the actual state of the SNS, as Folkow et al"l have cautioned.
We recorded renal sympathetic nerve activity (RSNA) in the conscious state to investigate the role of endogenous AVP and angiotensin II (Ang II) in modulating the baroreflex control of the SNS in two-kidney, one-clip hypertensive rabbits.12 The purpose of the present study was to elucidate how endogenous AVP interacts with the SNS and the RAS in the regulation of BP of renal-hypertensive rabbits. Contrary to previous studies that determined the relation of the pressor systems in the periphery, we examined the role of AVP in the central nervous system by infusing AVP antagonist into the vertebral artery. We advanced the hypothesis that, in renal hypertension, the SNS would be activated for BP maintenance when AVP is reduced and that the SNS would be exaggerated only when the RAS is attenuated. We also hypothesized that central and A. Renal Hypertensive V CAP NIC peripheral AVP interact differently with the SNS. In this study, we assessed the relative contributions of AVP, the RAS, and the SNS during different hypotensive challenges, and we chose drug regimens to produce equivalent decreases in MAP but to make very different profiles for the contribution of the pressor systems.
Materials and Methods General Preparations
Experiments were performed on 110 female Japanese White rabbits weighing 2.5-3.2 kg in accordance with the "Guiding Principles for Research Involving Animals and Humans" (Department of Health and Human Services, publication No. [NIH] . In surgery, anesthesia was induced with 30 mg/kg intravenous pentobarbital sodium and maintained with 6 mg kg-1 hr`pentobarbital. Three days before applying a renal clip (described below), polyethylene catheters (PE-60, Clay Adams, Parsippany, N.J.) were placed in the left subclavian artery for measuring the arterial BP and in the external jugular veins for administrations of drugs. These catheters were exteriorized at the back of the neck. The relative contributions of AVP, the SNS, and the RAS during different hypotensive challenges were assessed in conscious renal-hypertensive (n = 8) and normotensive (n =6) rabbits with intact baroreflex. The responses of MAP, RSNA, and HR to vehicle, captopril, and nicardipine were recorded continuously for 60 minutes. Mean RSNA just before drug administration was defined as 100%. Captopril and nicardipine were given in identical rabbits on different days (day 14 or 15), and the order of administration was determined in a randomized manner. On day 15, the examination with vehicle was performed at 4 hours before beginning the examination with captopril or nicardipine.
Protocol 2: Effects of Captopril and Nicardipine During Vertebral Artery Infusion ofAVP Antagonist
The purpose of this protocol was to examine how AVP interacts with the SNS to maintain BP in the central nervous system. The responses of MAP, HR, and RSNA during vertebral artery infusion of AVP antagonist d(CH2)5Tyr(Me)AVP (7 ng * kg.*min-1, diluted in saline, 42 ,li/min, Sigma) were recorded continuously for 30 minutes in six hypertensive and six normotensive rabbits. This dose of AVP antagonist had been determined to eliminate the pressor effect of 2.0 milliunits * kg`. min-1 i.v. AVP in our preliminary study. The responses to vehicle, captopril, and nicardipine during the vertebral artery infusion of AVP antagonist were recorded for the subsequent 60 minutes. RSNA before the AVP antagonist infusion was defined as 100%. AVP antagonist plus vehicle, AVP antagonist plus captopril, and AVP antagonist plus nicardipine were given in the same rabbits on different days (days [14] [15] [16] 
Plasma Concentrations of Neurohormones
To examine the effects of humoral factors on hemodynamics and neural element, additional renal-hypertensive and normotensive rabbits were prepared. Drugs were administered as in protocols 1, 4, and 6 in eight renal-clipped and six sham-clipped rabbits for each protocol. A 5-ml blood sample was taken 30 minutes after administration of the drug to determine the plasma concentrations of Ang 11, AVP, and norepinephrine. The plasma concentrations of Ang II and AVP were determined by radioimmunoassay2021 and that of norepinephrine by high-performance liquid chromatography. 22 The intraassay coefficients of variation for Ang II, AVP, and NE were 8.4%, 4 
Basal Values of MAP and HR
Fourteen days after the clipping, the MAP of renalclipped rabbits was significantly higher than that of sham-clipped rabbits ( Table 1) . The difference in basal MAP between normotensive and hypertensive rabbits was maintained after SAD. Although the MAP in SAD rabbits with renal hypertension was slightly higher than that of hypertensive rabbits with intact baroreflex, the difference was not significant. Since a nadir in the BP response to captopril was observed 30 minutes after the injection and the mode of nicardipine infusion was arranged to simulate the depressor sequence of captopril, the maximum responses of RSNA and HR were obtained at 30 minutes. In renalhypertensive rabbits, MAP was reduced by 10±1 and 11 ± 1 mm Hg with captopril and nicardipine, respectively ( Figure 1A and Table 2 ). The increase in RSNA induced by captopril (+68±4%) was significantly greater than that induced by nicardipine (+31±6%). The increase in HR was larger with nicardipine. Table 3 shows the plasma concentrations of Ang II, AVP, and NE. The concentrations of all neurohormones in hypertensive rabbits with intact baroreflex were significantly higher than those in normotensive rabbits (Table 3) . We compared the percent values of these concentrations in rabbits with intact baroreflex; each concentration with vehicle was defined as 100% ( Figure 2 ). In renal-hypertensive rabbits, the percent value of Ang II was 56±6% after captopril injection (Figure 2A ), a value that was significantly smaller than that produced by vehicle or nicardipine. In contrast, AVP was markedly increased to 255 ±24% by captopril. With nicardipine infusion, the percent values of Ang II and NE were higher than those with vehicle.
In normotensive rabbits ( Figure 1B) , neither captopril nor nicardipine changed BP, RSNA, or HR. There were no significant differences in concentrations of neurohormones after drug administration ( Figure 2B ).
Protocol 2: Effects of Captopril and Nicardipine
During Vertebral Arterial Infusion ofAVP Antagonist Figure 3A demonstrates that vertebral artery infusion of AVP antagonist did not significantly change either MAP, RSNA, or HR. By contrast, during the central infusion of AVP antagonist, reduction in MAP by captopril was associated with significant increases in RSNA (+112±6%) and HR. Reduction in MAP by nicardipine was also associated with significant increases in RSNA (+84±5%) and HR. Both values of RSNA during the vertebral artery infusion of AVP antagonist ( Figure 3A) were significantly (p<0.01) greater than those without the antagonist ( Figure 1A) . During the central infusion of AVP antagonist, the increase in RSNA by captopril was significantly larger than that by nicardipine.
Protocol 3: Effects of Captopril and Nicardipine During Intravenous Infusion ofA VP Antagonist
As shown in Figure 4 , MAP was significantly reduced, and RSNA was increased by 34+5% with intravenous AVP antagonist in conscious renal-hypertensive rabbits. Captopril and nicardipine further reduced MAPs during intravenous AVP antagonist infusion; the significant reductions in MAP were associated with significant increases in RSNA (+82+5% and +64±6%, respectively). The increases in RSNA with captopril and nicardipine during intravenous infusion of AVP antagonist were significantly (p<0.05) smaller than those during vertebral artery infusion of the antagonist.
Protocol 4: Effects of Captopril and Nicardipine in SAD Rabbits
In SAD rabbits with renal hypertension, captopril and nicardipine significantly reduced MAP ( Figure 5A and Table 2 ). The decrease in MAP with captopril in SAD rabbits with hypertension (30± 4 mm Hg) was significantly larger than that in hypertensive rabbits with intact baroreflex (10±1 mm Hg). No changes in RSNA and HR were observed despite the significant decreases in MAP. In SAD rabbits with normotension, the decreases in MAP induced by captopril and nicardipine were 18±3 and 8±3 mm Hg, respectively ( Figure SB) .
In SAD rabbits with renal hypertension, captopril did not decrease the plasma concentration of Ang II (Figure 6A ). Ang II was significantly increased with nicardipine as compared with the vehicle.
Protocol 5: Effects of Captopril and Nicardipine During Intravenous Infusion ofAVP Antagonist in SAD Rabbits
In SAD rabbits with renal hypertension, MAP was significantly reduced from 102± 5 to 84±4 mm Hg by 
Protocol 6: Effects of Captopril and Nicardipine During Clonidine Infusion
After a sharp increase, MAP gradually decreased by 10 ± 1 mm Hg 30 minutes after the initiation of clonidine in renal-hypertensive rabbits ( Figure 7A ). By adding captopril and nicardipine, MAP was reduced by 25±2 and 20±2 mm Hg, respectively. Thirty minutes after the initiation of clonidine, RSNA and HR were significantly reduced by 75±4% and 22±2 beats per minute, respectively. RSNA was elevated to +26±4% by injecting captopril and to -18±3% by injecting nicardipine. During clonidine infusion, the increase in RSNA by captopril (+101±6%) was significantly larger than that by nicardipine (+57±5%). Contrary to the difference in HR responses without clonidine, HR did not differ between captopril and nicardipine during clonidine infusion. In normotensive rabbits, MAP was decreased by 8±1 mm Hg, and RSNA and HR were reduced with clonidine ( Figure 7B ). MAP was decreased with captopril by 18±2 mm Hg, which was not different from that with nicardipine.
In renal-hypertensive rabbits, clonidine infusion resulted in suppression of basal plasma levels of Ang TI, AVP, and norepinephrine ( Table 3 ). The percent values of neurohormones during clonidine infusion are shown in Figure 8 . Captopril, compared with clonidine alone, significantly reduced Ang II. Even in the presence of clonidine, captopril significantly elevated plasma AVP (194±15%) and norepinephrine (190±12%). With nicardipine, Ang II was significantly increased.
Discussion
In the present study, we used RSNA recorded in the conscious state as an index of SNS function. Despite equivalent depressor effects, the responses of RSNA and AVP to captopril were different from those to nicardipine. After captopril injection, the increase in RSNA was greater, and plasma concentration of AVP was significantly increased (Figures 1A and 2 ). We speculate that these results were in part attributed to compensation for the attenuated RAS.
Therefore, we hypothesized that if AVP had been blocked, RSNA would be increased only by captopril but not by nicardipine. However, when AVP antagonist was infused in either the vertebral artery or the peripheral vein, RSNA was exaggerated in a nonspecific manner whether the RAS was attenuated or stimulated ( Figures 3A and 4) . These results show that when action of AVP was attenuated, the SNS could become the most important mechanism for BP support in conscious renal-hypertensive rabbits. Moreover, the interaction between AVP and the SNS seemed to be independent of the state of the SNS, since the exaggeration of RSNA induced by BP reduction with nicardipine was qualitatively the same as with captopril.
Intravenous AVP antagonist reduced MAP and increased RSNA, whereas vertebral artery infusion of AVP antagonist did not. During the central infusion of AVP antagonist, RSNA was exaggerated by BP reduction with captopril and nicardipine. The increases in RSNA to captopril and nicardipine were significantly larger during central attenuation of AVP than those with peripheral attenuation of AVP, despite the smaller magnitude of BP reduction. We presume that the In renal-hypertensive rabbits with SAD, the reduction in MAP by captopril was significantly larger than that in hypertensive rabbits with intact baroreflex, and the depressor effect was greater with captopril than with nicardipine. Both results may indicate that the RAS works as a compensatory mechanism to maintain BP when the baroreflex control of the SNS is eliminated. Therefore, the current data showed a close interaction between the RAS and the baroreflex in renal hypertension. In SAD rabbits with renal hypertension that were given captopril ( Figure 5 ), the intrarenal baroreceptor mechanism would be expected to operate powerfully on renin release, since the MAP was reduced by 30 mm Hg and the afferent limb of the baroreflex was interrupted.
Partially blocking the sympathetic outflow with clonidine did not abolish the enhanced response of RSNA and the increase in AVP made by captopril. AVP secretion was stimulated when both the SNS and RAS SAD plus Normotensive In normotensive rabbits, clonidine significantly decreased MAP, and captopril and nicardipine caused equivalent BP reductions in the presence of clonidine ( Figure 7B ), both of which mean that the SNS was the primary system for BP support. However, since captopril increased RSNA from that with clonidine alone and nicardipine did not, the RAS may have partly supported BP in conjunction with the SNS when the central sympathetic outflow was attenuated. In this regard, our results are not compatible with a previous report that AVP became a more important pressor system than the RAS after autonomic blockade.32 An earlier study by Hasser and Bishop3 showed that in SAD animals the role of the RAS is greater because the accentuated SNS enhances the RAS. This enhancement may explain the mechanism whereby captopril significantly reduced BP in the normotensive animals with SAD.
In hypertensive rabbits, the increase in HR was larger with nicardipine than with captopril despite the smaller increase in RSNA. Nicardipine may decrease vagal nerve activity more than does captopril. This speculation is based on a report that Ang II reduces the vagal activity. 33 We also presume that vagal nerve activity was not so attenuated or even facilitated with captopril. 34 The difference in HR responses between captopril and nicardipine was not observed during clonidine infusion. Levy and Zieske35 have shown that the slope of the curve between the vagal tone and changes in HR becomes dull when the vagal tone is high. One of the mechanisms by which the increase in HR was not so large with nicardipine in the presence of clonidine was the stimulation of the prevailing vagal tone by clonidine alone.
In summary, the principal finding of the present study is that compensatory activation of RSNA was revealed by central and peripheral attenuation of AVP and that the SNS became the most important mechanism for BP maintenance in the absence of AVP. The interaction of AVP with the SNS seemed to be independent of the state of the RAS, since the exaggeration of RSNA by AVP antagonist was qualitatively the same with nicardipine as with captopril. In conscious renal-hypertensive rabbits, AVP in the central nervous system played a substantial role when BP was reduced, although it did not contribute to BP maintenance in the basal condition.
